Abstract:T-cells play a critical role in tumor immunity. Indeed, the presence of tumor-infiltrating lymphocytes is a predictor of favorable patient prognosis for many indications and is a requirement for responsiveness to immune checkpoint blockade therapy targeting programmed cell death 1. For tumors lacking immune infiltrate, or for which antigen processing and/or presentation has been downregulated, a promising immunotherapeutic approach is chimeric antigen receptor (CAR) T-cell therapy. CARs are hybrid receptors that link the tumor antigen specificity and affinity of an antibody-derived single-chain variable fragment with signaling endodomains associated with T-cell activation. CAR therapy targeting CD19 has yielded extraordinary clinical responses against some hematological tumors. Solid tumors, however, remain an important challenge to CAR T-cells due to issues of homing, tumor vasculature and stromal barriers, and a range of obstacles in the tumor bed. Protumoral immune infiltrate including T regulatory cells and myeloid-derived suppressor cells have been well characterized for their ability to upregulate inhibitory receptors and molecules that hinder effector T-cells. A critical role for metabolic barriers in the tumor microenvironment (TME) is emerging. High glucose consumption and competition for key amino acids by tumor cells can leave T-cells with insufficient energy and biosynthetic precursors to support activities such as cytokine secretion and lead to a phenotypic state of anergy or exhaustion. CAR T-cell expansion protocols that promote a less differentiated phenotype, combined with optimal receptor design and coengineering strategies, along with immunomodulatory therapies that also promote endogenous immunity, offer great promise in surmounting immunometabolic barriers in the TME and curing solid tumors.

Engineering Chimeric Antigen Receptor-T Cells for Cancer Treatment

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

New Chimeric Antigen Receptor Design for Solid Tumors

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel

Current Clinical Application of the CAR-T Cell Therapy

Engineered T-cell Receptor T Cells for Cancer Immunotherapy

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

CAR-T cell therapy: current limitations and potential strategies

Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors

Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies